Inclusion Criteria for Heart Failure With Preserved Ejection Fraction Clinical Trials: Making the Case for Precision Diagnosis and Greater Inclusivity

Ravi B. Patel; Sanjiv J. Shah

doi:10.1016/j.cardfail.2022.03.345

Inclusion Criteria for Heart Failure With Preserved Ejection Fraction Clinical Trials: Making the Case for Precision Diagnosis and Greater Inclusivity

Ravi B. Patel, Sanjiv J. Shah^*

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Editorial › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	732-735
Number of pages	4
Journal	Journal of Cardiac Failure
Volume	28
Issue number	5
DOIs	https://doi.org/10.1016/j.cardfail.2022.03.345
State	Published - May 2022

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.cardfail.2022.03.345

Cite this

@article{331914cd64b64e4e84d83ad3561fd6dc,

title = "Inclusion Criteria for Heart Failure With Preserved Ejection Fraction Clinical Trials: Making the Case for Precision Diagnosis and Greater Inclusivity",

author = "Patel, {Ravi B.} and Shah, {Sanjiv J.}",

note = "Funding Information: Dr. Patel is supported by grant KL2TR001424 from the National Center for Advancing Translational Sciences, U.S. National Institutes of Health (NIH). Dr. Shah is supported by U54 HL160273, R01 HL107577, R01 HL140731, and R01 HL149423 from the National Heart, Lung, and Blood Institute of the NIH. Dr. Shah has received research grants from Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and has received consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics.",

year = "2022",

month = may,

doi = "10.1016/j.cardfail.2022.03.345",

language = "English (US)",

volume = "28",

pages = "732--735",

journal = "Journal of Cardiac Failure",

issn = "1071-9164",

publisher = "Churchill Livingstone",

number = "5",

}

TY - JOUR

T1 - Inclusion Criteria for Heart Failure With Preserved Ejection Fraction Clinical Trials

T2 - Making the Case for Precision Diagnosis and Greater Inclusivity

AU - Patel, Ravi B.

AU - Shah, Sanjiv J.

N1 - Funding Information: Dr. Patel is supported by grant KL2TR001424 from the National Center for Advancing Translational Sciences, U.S. National Institutes of Health (NIH). Dr. Shah is supported by U54 HL160273, R01 HL107577, R01 HL140731, and R01 HL149423 from the National Heart, Lung, and Blood Institute of the NIH. Dr. Shah has received research grants from Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and has received consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics.

PY - 2022/5

Y1 - 2022/5

UR - http://www.scopus.com/inward/record.url?scp=85129980213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85129980213&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2022.03.345

DO - 10.1016/j.cardfail.2022.03.345

M3 - Editorial

C2 - 35331890

AN - SCOPUS:85129980213

SN - 1071-9164

VL - 28

SP - 732

EP - 735

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

IS - 5

ER -

Inclusion Criteria for Heart Failure With Preserved Ejection Fraction Clinical Trials: Making the Case for Precision Diagnosis and Greater Inclusivity

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this